Bilateral Triple Negative Invasive Ductal Breast Carcinoma in a BRCA1 Mutation Carrier with Discrepant Pathologic Response to Neoadjuvant Chemotherapy

다국어 초록 (Multilingual Abstract)

Herein, we report a case of synchronous bilateral triple negative invasive ductal breast carcinoma in a patient with discrepant pathologic response to neoadjuvant chemotherapy. Right and left breast cancer stages at the initial diagnosis were T1cN0M0 and T4dN3aM0, respectively.
The patient was identified as a BRCA1 mutation carrier and treated with four cycles of adriamycin and cyclophosphamide, followed by four cycles of docetaxel. Bilateral breast cancer stages decreased with the first regimen. However, the bilateral breast cancers showed discrepant responses to chemotherapy with docetaxel. The right breast cancer showed a continuous tumor volume reduction while the left breast cancer showed marked progression. Finally, the tumor size was 0.3 cm and 12 cm in the right and left mastectomy specimens, respectively. As bilateral breast cancers of the same subtype may show discrepant responses to neoadjuvant chemotherapy, close monitoring and follow-up imaging are required to avoid delayed surgery.

참고문헌 (Reference)

1 Petrelli F, "The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers : a systematic review and meta-analysis" 144 : 223-232, 2014

2 Jones RL, "The prognostic significance of Ki67before and after neoadjuvant chemotherapy in breast cancer" 116 : 53-68, 2009

3 Liedtke C, "Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer" 26 : 1275-1281, 2008

4 Elnemr GM, "Response of triple negative breast cancer to neoadjuvant chemotherapy : correlation between Ki-67 expression and pathological response" 17 : 807-813, 2016

5 Wang C, "Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer" 26 : 523-528, 2015

6 Turner NC, "Platinum chemotherapy for BRCA1-related breast cancer : do we need more evidence" 14 : 115-, 2012

7 Siew Kuan Lim, "Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome" 대한암학회 48 (48): 133-141, 2016

8 Lehmann BD, "Identification of human triplenegative breast cancer subtypes and preclinical models for selection of targeted therapies" 121 : 2750-2767, 2011

9 Masuda H, "Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes" 19 : 5533-5540, 2013

10 Purkayastha A, "A rare case of triple negative synchronous bilateral invasive ductal carcinoma of breast" 4 : 67-71, 2016